Marc Beer: The Reason Behind Renovia
Renovia is Marc Beer’s latest biotechnology triumph. He co-founded the company in 2016 in Boston, MA alongside Dr. Ray Iglesias and Yolanda Lorie. Marc Beer is Chairman and CEO of the company, but it was almost not meant to be. If it weren’t a phone call, Beer could’ve still been retired.
Luckily, Beer was ready to come out of retirement, and Dr. Iglesias was close enough to develop a new product line and needed help getting that product line out to the public. Though Beer is leading the company, Renovia would never have happened without Dr. Iglesias’s compassion for his patients.
Dr. Iglesias is a gynecologist who specialized in pelvic floor surgeries simply because there was no other option for women. He always wished there was a product out there that women could rely on before their condition worsened to the point of needing surgery. After 35 years of performing pelvic floor surgeries, Dr. Iglesias took the initiative to create such a product.
After that first phone call, Marc Beer looked into the plausibility of Dr. Iglesias’s business and found that almost one-fourth of American women suffer from pelvic floor disorders. Even more appalling are the ambulatory costs since 2005. Beer immediately recognized pelvic floor disorders as a serious problem and joined Dr. Iglesias in his efforts to provide relief. Learn more: https://firstname.lastname@example.org
In Beer’s words, Renovia is trying to develop a successful combination of innovative technologies and a digital health platform. In more understandable terms, Renovia hopes to one day provide first-line diagnosis and treatment through a series of therapeutic and diagnostic devices for women. Pelvic floor disorders, while unknown to most, can cause pelvic organ prolapsed and urinary and fecal incontinence.
In 2018, Renovia made two spectacular steps in the right direction. Firstly, Renovia released its first FDA-approved product, Leva, in April. Secondly, Beer acquired a Series B round of funding from Perceptive Advisors of New York and Ascension Ventures of Missouri. A longtime investor in Renovia, The Longwood Fund, also contributed to the Series B funding Renovia received. The Series B gave Renovia $32 million.
Like with all unknown physical and mental health problems, pelvic floor disorders have a stigma around them. The first step to helping women with these disorders is removing the stigma because the stigma is preventing millions of women from seeking medical advice until it’s too late. That also contributes to why so many women had no other choice but to receive surgery.